Ximelagatran
![Ximelagatran Was Non-Inferior to Warfarin in Preventing Stroke and Oral Thrombin Inhibitor in Atrial Fibrillation [SPORTIF])](http://data.docslib.org/img/264x/2ad994af361de45e77124e9200ed2aa7.webp)
Top View
- Comparison of the Oral Direct Thrombin Inhibitor
- Ximelagatran: an Oral Direct Thrombin Inhibitor
- Drug Repositioning and Indication Discovery Using Description Logics
- Human and Veterinary Pharmaceuticals, Narcotics, And
- Direct Thrombin Inhibitors: Novel Antithrombotics on the Horizon in the Thromboprophylactic Management of Atrial Fibrillation R Katira, a Chauhan, R S More
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- SPAF-3 Slideset #4
- Exanta (Ximelagatran)
- ANTICOAGULANT, THROMBOLYTIC, and ANTI-PLATELET DRUGS
- Ag-Atc-Beschluss-20151127.Pdf
- <I>In Vitro</I> Biotransformation of the New Oral
- Relative Antithrombotic and Antihemostatic Effects of Protein C Activator Versus Low-Molecular-Weight Heparin in Primates
- Previous Drug Exposure in Patients Hospitalised
- Exanta® 3 Mg/0.3 Ml Melagatran Solution for Injection
- Development of New Anticoagulants: Present and Future
- 022406Orig1s000
- Rivaroxaban (Xarelto), and Apixaban (Eliquis) September 2013 VHA Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives
- Bmj.E7498.Full.Pdf